Works matching IS 15608115 AND DT 2024 AND VI 32 AND IP 1

Evaluation of time-to-onset and outcome of cardiac adverse events related to pembrolizumab using post-marketing surveillance in Japanese patients.

Published in:

DARU: Journal of Pharmaceutical Sciences, 2024, v. 32, n. 1, p. 279, doi. 10.1007/s40199-024-00516-z

By:

• Kanbayashi, Yuko;
• Tsuchiya, Eren;
• Shimizu, Tadashi;
• Uchida, Mayako

Publication type:

Article